 EXFORGE D
|
Novartis
|
| valsartán+hidrocloroti.+amlodip. |
Antihipertensivo |
| 160/12.5/10 mg comp.x 28 | $2,393.37 | (09/03/2020) |
| SIFAR |
Producto Reconocido |
|
| PAMI |
|
| AF $1,061.22 |
|
|
|
|
| 160/12.5/5 mg comp.x 28 | $2,416.38 | (09/03/2020) |
| SIFAR |
Producto Reconocido |
|
| PAMI |
|
| AF $1,071.41 |
|
|
|
|
| 160/25/10 mg comp.x 28 | $2,416.38 | (09/03/2020) |
| SIFAR |
Producto Reconocido |
|
| PAMI |
|
| AF $1,071.41 |
|
|
|
|
| 160/25/5 mg comp.x 28 | $2,416.38 | (09/03/2020) |
| SIFAR |
Producto Reconocido |
|
| PAMI |
|
| AF $1,071.41 |
|
|
|
|
| 320/25/10 mg comp.x 28 | $2,510.22 | (09/03/2020) |
| SIFAR |
Producto Reconocido |
|
| PAMI |
|
| AF $1,113.03 |
|
|
|
|
| |
